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designer peptide in the treatment of cardiovascular diseases such as
hypertensive crisis and acute decompensated CHF.
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THE ORALLY ACTIVE RENIN INHIBITOR SPP100
BLOCKS THE RENIN-ANGIOTENSIN SYSTEM IN
HUMANS EQUALLY WELL AS ENALAPRIL
Juerg Nussberger, Gregoire Wuerzner, Chris Jensen, Hans R.
Brunner. 1Division of Hypertension, University Hospital, Lausanne,
Switzerland, 2Speedel Pharma AG, Basel, Switzerland
The activity of the renin-angiotensin system (RAS) is mainly determined
by the concentration of active renin. Direct inhibition of renin is therefore
a primary goal for blocking the RAS. So far, all specific renin inhibitors
lacked potency or were clinically ineffective after oral administration. We
tested the new orally active non-peptidic renin inhibitor SPP100 in 18
healthy volunteers on a constant sodium diet (100 mmol/day)using a
double-blind, threeway crossover protocol. In 3 periods of 8 days, sep-
arated by wash-outs of 1 week, each volunteer received 2 dosage levels
of SPP100 once a day (40,80,160 or 640mg) and placebo or 20mg
enalapril. SPP100 was well tolerated. Not surprisingly, blood pressure
and heart rate remained unchanged in these normal volunteers. SPP100
plasma levels showed that steady state was reached after 8 days of
dosing. The table below summarizes median plasma levels at peak (P,
0.5-6h) and trough (T, 24h after dosing)on day 8: In conclusion, the renin
inhibitor SPP100 dose-dependently blocks the RAS and decreases an-
giotensin levels in human subjects following oral administration. The
effect is long-lasting and at 160mg at least equivalent to that of 20mg
enalapril. SPP100 has the clear potential to become the first renin
inhibitor that provides a true alternative to ACE-inhibitors and Ang II
receptor antagonists in the therapy of hypertension, cardiovascular and
renal disease.
Placebo SPP 100 Enalapril
40mg 80mg 160mg 640mg 20mg
Renin pg/ml P 12 34 95 130 670 330
T 11 19 39 64 373 58
PRA ng/ml/h P 1.0 0.28 0.21 0.16 0.08 27
T 1.4 0.89 0.60 0.41 0.39 3.5
Ang I fmol/ml P 3.2 1.6 1.4 0.33 0.70 350
T 7.0 7.1 6.1 4.8 3.1 34
Ang II fmol/ml P 3.0 1.5 1.5 0.61 0.27 0.88
T 4.5 3.7 3.5 3.2 2.5 4.2
Grant/Research Support: SPEEDEL PHARMA Concultant to SPEEDEL
PHARMA
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EFFECT OF VASOPEPTIDASE INHIBITION
BMS189921 ON PI3-KINASE SIGNALING IN VSMCS
E. Isenovic, N.Z. Jamali, Y. Rao, N. Milivojevic, M. Webber*, J.R.
Sowers*. 1Department of Medicine and Cell Biology, SUNY-Downstate
Medical Center at Brooklyn NY, United States,2The Bristol-Myers
Squibb Pharmaceutical Research Institute, Princeton, NJ, United
States
We investigated the effects of new vasopeptides inhibitor BMS189921 on
PI3-kinase (PI-K) protein expression in rat male and female vascular
smooth muscle cells (VSMCs).
VSMCs were prepared from male and female rats and treated for 15
and 30 min, with 5,10,20 and 100 mM of BMS189921 (Bristol-Mayer
Squibb Company). PI3-K protein expression was measured by immuno-
blot analysis.
BMS induced PI3-K protein expression at all doses and either times in
female VSMCS. The maximum effect of BMS in female VSMCs on
PI3-kinase protein expression was detected at a dose of 5 mM, 15 min
after treatment. This increase was 10.2 - fold compared to control values.
In contrast exposure of male VSMCs to BMS for 15 min and 30 min
did not significantly increase PI3-kinase protein expression.
These results indicate that vasopeptide inhibition by BMS189921, in
VSMCs activate the PI3-kinase signaling pathway. As PI3-Kinase acti-
vation promotes nitric oxide production, this pathway may mediate
vasorelaxation of BMS 189921 in female VSMCs.
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EFFECT OF DELAPRIL AND IRBESARTAN ON
PLASMA PAI-1 AND FIBRINOGEN IN
HYPERTENSIVE TYPE 2 DIABETIC PATIENTS
R. Fogari, A. Mugellini, A. Zoppi, L. Corradi, R. M. Pesce, P. Preti,
P. Lazzari, G. D. Malamani. 1Department of Internal Medicine and
Therapeutics, IRCCS Policlinico S. Matteo, University of Pavia, Pavia,
Italy
The aim of this study was to compare the effect of Delapril and Irbesartan
on PAI-1 and Fibrinogen in hypertensive type 2 diabetic patients, a
population with a known impaired fibrinolysis.
We studied 80 mild to moderate hypertensive patients (DBP.90 and
#100 mmHg) with well controlled NIDDM, aged 45 to 65 years. Smoker
patients were excluded. After a 4 week wash-out placebo period patients
were randomly assigned to receive Delapril 30 mg o.d. (n540) or
Irbesartan 150 mg o.d. (n540) for 12 weeks according to a randomized
parallel group design. At the end of the placebo period and of the active
treatment period blood pressure was measured and blood samples were
taken to evaluate plasma PAI-1, fibrinogen, glucose, HbA1c, cholesterol
and triglycerides.
The main results are as follows:
Placebo Delapril Placebo Irbesartan
SBP 154 6 12 139 6 10** 153 6 13 140 6 11**
DBP 95 6 4 83 6 6** 96 6 4 85 6 7**
PAI-1 (ng/ml) 39 6 19 29 6 15* 37 6 18 48 6 17*°
Fibrinogen(mg/dl) 338 6 66 322 6 59 331 6 67 342 6 65
* p , 0,05; ** p , 0,01 vs placebo; ° p , 0,05 vs Delapril
No treatment significantly influenced blood glucose, HcA1c and lipid
values. These results show that Delapril decreases PAI-1 levels in hy-
pertensive type 2 diabetic patients, while Irbesartan increases it. It sug-
gests that this effect is unrelated with AT-1 receptor blockade: it could be
due to the fact that the endothelial receptors that mediate PAI-1 expres-
sion in response to Angiotensin II are not type 1 receptor subtypes.
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COMPARATIVE EFFECTS OF THE DUAL ACE AND
VASOPEPTIDASE INHIBITOR MDL-100,240 AND
RAMIPRIL ON HYPERTENSION AND
CARDIOVASCULAR DISEASE (CVD) IN
ENDOGENOUS ANGIOTENSIN II-DEPENDENT
HYPERTENSION
Gian Paolo Rossi, Alfredo Sacchetto, Damiano Rizzoni, Sergio Bova,
Giuseppina Mazzocchi, Enrico Agabiti-Rosei, Gastone G. Nussdorfer,
Achille C. Pessina. 1Dept. of Clinical & Experimental Medicine-
Clinica Medica 4, University of Padua, Padua, Italy, 2Dept. of
Pharmacology, University of Padua, Padua, Italy, 3Dept. of Human
Anatomy & Physiology, University of Padua, Padua, Italy
We investigated the effects of MDL-100,240, a novel inhibitor with a
balanced inhibitory activity on ACE and vasopeptidases, on regression of
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